State of the Union: Advances in the Management HER2+ mBC

State of the Union: Advances in the Management HER2+ mBC  

State of the Union: Advances in the Management HER2+ mBC

Find out how our evolving understanding of HER2 status is dramatically changing the prognosis for patients with HER2+ metastatic breast cancer.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    HER2-directed antibody-drug conjugates (ADCs) are showing great promise in HER2+ metastatic breast cancer and are transforming the treatment paradigm. This chapterized activity examines the importance of HER2 status and incorporates a case presentation to demonstrate optimal therapy selection and the management of adverse events. Drs. Javier Cortes and Sara Hurvitz also examine efficacy and safety data of currently available and investigational agents. Tune in to explore exciting new therapies and the role they can play in improving outcomes for your patients with HER2+ metastatic breast cancer.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.


    Javier Cortes, MD, PhD
    Head, Breast Cancer Program
    IOB Institute of Oncology
    Madrid & Barcelona

    Consulting Fees: AstraZeneca, Athenex, Bioasis, BioInvent, Biothera Pharmaceutical, Boehringer Ingelheim, Celgene, Cellestia, Clovis Oncology, Daiichi Sankyo, Eisai, Ellipses, Erytech, GEMoaB, GSK, HiberCell, Kyowa Kirin, Leuko, Lilly, Merck Sharp & Dohme, Merus, Novartis, Pfizer, Polyphor, Roche, Samsung Bioepis, Seattle Genetics, Servier
    Contracted Research: Research funding to the Institution: ARIAD Pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffmann-La Roche, Guardant Health, Merck Sharp & Dohme, Pfizer, PIQUR Therapeutics, Puma C, Queen Mary University of London, Roche
    Ownership Interest: MEDSIR

    Sara A. Hurvitz, MD, FACP
    Associate Professor of Medicine
    Los Angeles, CA

    Contracted Research: Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, Daiichi Sankyo, Dignitana, Genentech/Roche, Gilead, GSK, Immunomedics, Lilly, MacroGenics, Novartis, OBI Pharma, Pfizer, Phoenix Molecular Designs, Ltd., Pieris, Puma, Radius, Samumed, Sanofi, Seattle Genetics, Zymeworks
    Ownership Interest: NKMax (self), ROMTech, Ideal Implant (spouse)

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Demonstrate optimal therapy selection based on individual patient characteristics in the HER2-positive metastatic breast cancer setting
    • Formulate strategies to manage potential adverse events associated with current treatment options for HER2-positive metastatic breast cancer
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, pathologists, and other healthcare professionals treating breast cancer.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free